Global Hodgkins Lymphoma Market to Reach US $1.4 Bn by 2024, Label Extensions of Brentuximab Vedotin to Drive Growth

MarketResearchReports.Biz presents this most up-to-date research on "OpportunityAnalyzer: Hodgkins Lymphoma (HL) - Opportunity Analysis and Forecasts to 2024".


Albany, NY -- (SBWIRE) -- 05/04/2016 -- has announced the addition of a new research report that offers a complete overview of the global hodgkins lymphoma (HL) market and evaluates the historical as well as the current performance of this market.

The research report, titled, "OpportunityAnalyzer: Hodgkins Lymphoma (HL) - Opportunity Analysis And Forecasts To 2024," mainly focuses on the therapeutic landscape of hodgkins lymphoma in the global arena.

Hodgkins lymphoma, commonly known as hodgkins disease, is a type of cancer in the lymphatic system of an individual. HL is a relatively rare type of cancer, holding a share of 12% in the overall incidence of lymphomas reported across the world and a share of 0.6% in the total number of new cancer cases. However, experts have predicted a rapid increase in the prevalence of HL over the next few years.

According to the market study, the global market for HL, primarily including the market for therapeutics used for the treatment of HL, stood at a value of US$316 mn in 2014. Analysts predict this market to report a four-fold rise at an impressive CAGR of 16.0% during the period from 2014 to 2024 and attain an estimated value of US$1.4 bn by the end of the forecast period.

View Press Release Report at:

The label extensions of brentuximab vedotin by Adcetris in the earlier lines of HL therapy is expected to boost the growth of the global HL market significantly over the forecast period. The rapid adoption of premium-priced products, such as nivolumab by Opdivo and pembrolizumab by Keytruda in the worldwide healthcare industry is also projected to propel this market in the coming years. Analysts expect Adcetris to lead and Opdivo and Keytruda to hold a significant share in the overall market over the forecast period.

The report also predicts pipeline agents to take a lead over conventional care therapies utilized for the treatment of HL over the forecast period. Further, its states that new entrants are likely to face a severe challenge from high unmet requirements of relapsed or refractory HL patients.

In this research report, the U. K., the U.S., France, Italy, Germany, Japan, and Spain have been identified as the key regional markets for HL in the global arena.

For Sample Copy, click here:

The research study also studies the competitive landscape of the global HL market by examining the company profiles of the major enterprises operating in this market. Linus Oncology, Novartis, Mirati Therapeutics, Affimed Therapeutics, Cell Medica Ltd., Kyowa Hakki Kirin, 4SC, Actinium Pharmaceuticals, Incyte Corp., Millennium Pharmaceuticals, Acetylon Pharmaceuticals, Bellicum Pharmaceuticals, Bristol-Myers Squibb, Cellular Biomedicine Group, Johnson & Johnson, NantKwest, and ADC Therapeutics are the leading players in the hodgkins lymphoma therapeutics market, states the research study.

About is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact us:
State Tower
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA: Canada Toll Free: 866-997-4948
E :